Karen A G Takazaki1, Thiago Quinaglia2, Thiago D Venancio1, Alberto R M Martinez1, Ravi V Shah3, Tomas G Neilan3, Michael Jerosch-Herold4, Otávio R Coelho-Filho2, Marcondes C França1. 1. Division of Medicine, Section of Neurology, Department of Neurology, School of Medical Sciences, University of Campinas - UNICAMP, Campinas, São Paulo, Brazil. 2. Division of Medicine, Section of Cardiology, Department of Internal Medicine, Division of Medicine, Section of Neurology, School of Medical Sciences, University of Campinas - UNICAMP, Campinas, São Paulo, Brazil. 3. Division of Medicine, Section of Cardiovascular Imaging Research Program and Cardiac MR PET CT Program, Department of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States of America. 4. Division of Medicine, Section of MRI Physics, Department of Radiology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States of America.
Abstract
BACKGROUND: Heart Failure (HF) is the most common cause of death in Friedreich's ataxia (FRDA), an inherited mitochondrial disease. Myocardial fibrosis and myocardial hypertrophy are well-documented autopsy features among FRDA patients with HF. OBJECTIVES: To leverage the unique tissue characterization features of cardiac magnetic resonance (CMR) for characterizing myocardial remodeling in patients with genetically confirmed FRDA without HF and preserved left ventricular ejection fraction (LVEF > 55%). METHODS: Twenty-seven FRDA's patients (age 27.6 ± 9.7 years, 15 women) and 10 healthy controls (32.6±7.3 years, 5 women) underwent a CMR for assessment of LV function, myocardial T1, late gadolinium enhancement (LGE), extracellular volume fraction (ECV), and intracellular water-lifetime (τic), a marker of cardiomyocyte size. RESULTS: As compared to controls, FRDA patients had a preserved LVEF (LVEF: 70.5±7.4% vs. 63.9±9.0%, P<0.058), larger LV mass index (LVMASSi: 61±21.7 vs. 45±4.2g/m2, P<0.02), and decreased LV end-diastolic volume index (LVEDVi 53.1±12.0 vs. 75.7±16.1ml/m2, P<0.001), compared with controls. Additionally, ECV and cardiomyocyte size (τic,) were larger in FRDA patients (ECV: 0.36 ±0.05 vs. 0.25±0.02, P<0.001; τic: 0.15±0.08 vs. 0.06±0.03 s, P = 0.02). ECV and τic were positively associated with LV mass-to-volume ratio (ECV: r = 0.57, P = 0.003; τic: r = 0.39; P = 0.05). LVMASSi and cardiomyocyte mass-index [(1-ECV)·LVMASSi] declined with age at the CMR exam, independent of the age at initial diagnosis. CONCLUSIONS: LV hypertrophy and concentric LV remodeling in FRDA are associated at the tissue level with an expansion of the ECV and an increase in cardiomyocyte size. The adverse tissue remodeling assessed by ECV and τic is associated with more severe cardiomyopathy classification, suggesting a role for these markers in tracking disease progression.
BACKGROUND:Heart Failure (HF) is the most common cause of death in Friedreich's ataxia (FRDA), an inherited mitochondrial disease. Myocardial fibrosis and myocardial hypertrophy are well-documented autopsy features among FRDApatients with HF. OBJECTIVES: To leverage the unique tissue characterization features of cardiac magnetic resonance (CMR) for characterizing myocardial remodeling in patients with genetically confirmed FRDA without HF and preserved left ventricular ejection fraction (LVEF > 55%). METHODS: Twenty-seven FRDA's patients (age 27.6 ± 9.7 years, 15 women) and 10 healthy controls (32.6±7.3 years, 5 women) underwent a CMR for assessment of LV function, myocardial T1, late gadolinium enhancement (LGE), extracellular volume fraction (ECV), and intracellular water-lifetime (τic), a marker of cardiomyocyte size. RESULTS: As compared to controls, FRDApatients had a preserved LVEF (LVEF: 70.5±7.4% vs. 63.9±9.0%, P<0.058), larger LV mass index (LVMASSi: 61±21.7 vs. 45±4.2g/m2, P<0.02), and decreased LV end-diastolic volume index (LVEDVi 53.1±12.0 vs. 75.7±16.1ml/m2, P<0.001), compared with controls. Additionally, ECV and cardiomyocyte size (τic,) were larger in FRDApatients (ECV: 0.36 ±0.05 vs. 0.25±0.02, P<0.001; τic: 0.15±0.08 vs. 0.06±0.03 s, P = 0.02). ECV and τic were positively associated with LV mass-to-volume ratio (ECV: r = 0.57, P = 0.003; τic: r = 0.39; P = 0.05). LVMASSi and cardiomyocyte mass-index [(1-ECV)·LVMASSi] declined with age at the CMR exam, independent of the age at initial diagnosis. CONCLUSIONS:LV hypertrophy and concentric LV remodeling in FRDA are associated at the tissue level with an expansion of the ECV and an increase in cardiomyocyte size. The adverse tissue remodeling assessed by ECV and τic is associated with more severe cardiomyopathy classification, suggesting a role for these markers in tracking disease progression.
Authors: Elisabetta Soragni; Wenyan Miao; Marco Iudicello; David Jacoby; Stefania De Mercanti; Marinella Clerico; Filomena Longo; Antonio Piga; Sherman Ku; Erica Campau; Jintang Du; Pablo Penalver; Myriam Rai; Joseph C Madara; Kristopher Nazor; Melinda O'Connor; Anton Maximov; Jeanne F Loring; Massimo Pandolfo; Luca Durelli; Joel M Gottesfeld; James R Rusche Journal: Ann Neurol Date: 2014-09-16 Impact factor: 10.422
Authors: Martin St John Sutton; Bonnie Ky; Sean R Regner; Kim Schadt; Ted Plappert; Jiwei He; Benjamin D'Souza; David R Lynch Journal: Echocardiography Date: 2013-07-09 Impact factor: 1.724
Authors: L Seyer; N Greeley; D Foerster; C Strawser; S Gelbard; Y Dong; K Schadt; M G Cotticelli; A Brocht; J Farmer; R B Wilson; D R Lynch Journal: Acta Neurol Scand Date: 2014-10-21 Impact factor: 3.209
Authors: A Dürr; M Cossee; Y Agid; V Campuzano; C Mignard; C Penet; J L Mandel; A Brice; M Koenig Journal: N Engl J Med Date: 1996-10-17 Impact factor: 91.245
Authors: Pamela C Kruger; Karl X Yang; Patrick J Parsons; Alyssa B Becker; Paul J Feustel; Arnulf H Koeppen Journal: Am J Cardiol Date: 2016-04-20 Impact factor: 2.778
Authors: Chris Meyer; Gebhard Schmid; Sabine Görlitz; Monika Ernst; Christian Wilkens; Inga Wilhelms; Peter H Kraus; Peter Bauer; Jürgen Tomiuk; Horst Przuntek; Andreas Mügge; Ludger Schöls Journal: Mov Disord Date: 2007-08-15 Impact factor: 10.338
Authors: Otavio R Coelho-Filho; Ravi V Shah; Richard Mitchell; Tomas G Neilan; Heitor Moreno; Bridget Simonson; Raymond Kwong; Anthony Rosenzweig; Saumya Das; Michael Jerosch-Herold Journal: Circulation Date: 2013-08-02 Impact factor: 29.690
Authors: Ashley McCormick; Jennifer Farmer; Susan Perlman; Martin Delatycki; George Wilmot; Katherine Matthews; Grace Yoon; Chad Hoyle; Sub H Subramony; Theresa Zesiewicz; David R Lynch; Shana E McCormack Journal: Ann Clin Transl Neurol Date: 2017-07-26 Impact factor: 4.511
Authors: Marie Beaudin; Mario Manto; Jeremy D Schmahmann; Massimo Pandolfo; Nicolas Dupre Journal: Nat Rev Neurol Date: 2022-03-24 Impact factor: 42.937